Skip to Content


View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Additional Indications for UCB's Bimzelx Could Drive Growth as Generics Weigh on Portfolio

Business Strategy and Outlook

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid pharma/chemical firm into a pure-play biopharmaceutical company by shedding its packaging, film, and chemical businesses. Acquisitions of Celltech (2004) and Schwarz Pharma (2006) strengthened the biopharmaceutical pipeline, bringing in late-stage assets that would eventually be approved as Cimzia (immunology), Vimpat (epilepsy), and Neupro (Parkinson's disease). These key products helped offset the impact of Zyrtec and Keppra's patent losses, and the company has continued to shape its expertise in immunology and central nervous system disorders.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of UCB so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center